Apricus Biosciences Sells Totect for Bicodex Labs Unit

Apricus Biosciences, Inc.("Apricus Bio" or the "Company") (Nasdaq: APRI) (www.apricusbio.com) todayannounced the sale of (1) Totect^® (dexrazoxane HCl), a marketed, injectabletreatment for anthracycline extravasation, and (2) NitroMist^® (nitroglycerinsublingual aerosol), an FDA-approved nitrate vasodilator indicated for acuterelief of an attack or acute prophylaxis of angina pectoris due to coronaryartery disease. In line with its previously stated corporate strategy, theCompany is focusing its resources on commercializing its lead productVitaros^® (alprostadil 0.3% topical cream), for the treatment of erectiledysfunction ("ED"), and on the development of Femprox^® (alprostadil 0.4%topical cream), for the treatment of female sexual arousal disorder ("FSAD").Totect^® was acquired by Biocodex USA ("Biocodex"), a subsidiary of aprivately-held, French pharmaceutical company, Biocodex Laboratories. Underterms of the Biocodex agreement, Apricus Bio received an upfront payment atclosing and is eligible to receive royalties on net sales of Totect^® byBiocodex through 2016, in exchange for Apricus Bio's sale of itscommercialization rights to Totect^® in North America and South America.NitroMist^® was acquired by Mist Pharmaceuticals, LLC ("Mist"), a privatelyheld specialty pharmaceutical company. Mist will receive rights tocommercialize and market NitroMist^® in all countries outside the U.S., Canadaand Mexico.